Free Trial

ProKidney Q2 2023 Earnings Report

ProKidney logo
$0.83 -0.05 (-5.27%)
As of 04/1/2025 04:00 PM Eastern

ProKidney EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.41
Beat/Miss
Beat by +$0.27
One Year Ago EPS
N/A

ProKidney Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ProKidney Announcement Details

Quarter
Q2 2023
Time
N/A
Remove Ads

ProKidney Earnings Headlines

ProKidney Corp.
Brace Yourself for Jeff Bezos’ “Amazon Helios”
Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical technology that could change society forever and make early investors rich.
ProKidney reports FY24 EPS (62c), consensus (59c)
See More ProKidney Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ProKidney? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProKidney and other key companies, straight to your email.

About ProKidney

ProKidney (NASDAQ:PROK), a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

View ProKidney Profile

More Earnings Resources from MarketBeat